Silvan Tuerkcan
Stock Analyst at JMP Securities
(3.39)
# 998
Out of 4,996 analysts
172
Total ratings
47.31%
Success rate
3.83%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTC Benitec Biopharma | Reiterates: Market Outperform | $20 | $13.51 | +48.04% | 13 | Sep 24, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $2.47 | +142.91% | 7 | Sep 22, 2025 | |
| NTLA Intellia Therapeutics | Reiterates: Market Perform | n/a | $16.31 | - | 11 | Sep 19, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $23.62 | +43.95% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $26.83 | +67.72% | 2 | Sep 8, 2025 | |
| EXEL Exelixis | Reiterates: Market Outperform | $50 | $39.04 | +28.07% | 23 | Jul 29, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $61.67 | +39.45% | 16 | Jun 27, 2025 | |
| NUVB Nuvation Bio | Reiterates: Market Outperform | $6 | $3.20 | +87.50% | 3 | Jun 25, 2025 | |
| SLDB Solid Biosciences | Reiterates: Market Outperform | $15 | $6.15 | +143.90% | 3 | Jun 6, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $5 → $6 | $3.25 | +84.62% | 13 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $5.12 | +17.19% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $4.86 | +85.19% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $33.62 | +256.93% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $6.49 | +177.35% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $20 | $7.64 | +161.78% | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.66 | +924.10% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $6.00 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $0.91 | +339.56% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $5.17 | +306.19% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.73 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.32 | +80.72% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $206.59 | +35.53% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $9.84 | +82.93% | 1 | Jan 26, 2023 |
Benitec Biopharma
Sep 24, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $13.51
Upside: +48.04%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $2.47
Upside: +142.91%
Intellia Therapeutics
Sep 19, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $16.31
Upside: -
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $23.62
Upside: +43.95%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $26.83
Upside: +67.72%
Exelixis
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $39.04
Upside: +28.07%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $61.67
Upside: +39.45%
Nuvation Bio
Jun 25, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.20
Upside: +87.50%
Solid Biosciences
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $6.15
Upside: +143.90%
Taysha Gene Therapies
May 29, 2025
Maintains: Market Outperform
Price Target: $5 → $6
Current: $3.25
Upside: +84.62%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $5.12
Upside: +17.19%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $4.86
Upside: +85.19%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $33.62
Upside: +256.93%
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $6.49
Upside: +177.35%
Apr 21, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $7.64
Upside: +161.78%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.66
Upside: +924.10%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $6.00
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $0.91
Upside: +339.56%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $5.17
Upside: +306.19%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.73
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $3.32
Upside: +80.72%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $206.59
Upside: +35.53%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $9.84
Upside: +82.93%